Drug Profile
Abatacept biosimilar - Momenta Pharmaceuticals
Alternative Names: M-834Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Momenta Pharmaceuticals
- Developer Momenta Pharmaceuticals; Mylan
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 01 Oct 2020 Momenta Pharmaceuticals has been acquired by Johnson & Johnson
- 28 Dec 2019 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in United Kingdom (Parenteral, Injection)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in United Kingdom (Parenteral, Injection)